Repligen (NASDAQ:RGEN), a bioprocessing technology company ... but in line with the 20.9% result it achieved in Q4. Moreover, it guided for adjusted EPS of between $1.67 and $1.76, up from ...
Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss. Find out why I remain bullish on EXAS stock.
EPS: $1.24 in Q4 vs. -$3.23 in the same period last year ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
EPS: $0.15 in Q4 vs. -$0.05 in the same period last year ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
EPS: -$1.00 in Q4 vs. $0.48 in the same period last year ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
EPS: $0.08 in Q4 vs. -$0.07 in the same period last year ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
EPS: -$0.02 in Q4 vs. $0.76 in the same period last year ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
EPS: $0.33 in Q4 vs. -$0.15 in the same period last year ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
$127.4 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
$512.3 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
$339.19 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...